Strong topline growth driven by solid performance across key brands.
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Subscribe To Our Newsletter & Stay Updated